Marco Purbhoo

Marco Purbhoo has extensive work experience in the field of biomedical research and development. Marco is currently serving as the Director of Translational Research at MiNK Therapeutics since May 2020. Prior to this, they worked as a Principal Scientist at Cell Medica from May 2015 to November 2019. Marco has also held various roles at prestigious institutions such as Imperial College London, Stanford University, and the University of Oxford. At Imperial College London, they served as a Principal Investigator and Assistant Professor, leading research on T cell and NK cell responses to liver-associated viruses. Marco was also a Senior Post-Doctoral Scientist, conducting research on the molecular mechanisms of T cell and NK cell antigen recognition. Marco's research has been funded by the Wellcome Trust. Marco has also worked as a Senior Scientist at Avidex Ltd (now Immunocore). Marco began their research career as a Research Fellow at Stanford University, where they focused on molecular mechanisms underlying antigen recognition and signal transduction. Marco completed their Ph.D. at the University of Oxford, where they conducted research as a Ph.D. student. Overall, Marco Purbhoo has a broad range of experience in biomedical research and has made significant contributions to the field.

Marco Purbhoo has a diverse education history. In 1977, they attended the International School of Hamburg (ISH), where they pursued their International Baccalaureat (Bilingual) degree, specializing in Immunology. In 1989, they enrolled at the University of Oxford, where they completed their Master's Degree in Biochemistry, which they pursued until 1994. Following this, Marco attended Oriel College, Oxford, from 1995 to 1999, where they obtained their D. Phil. in Clinical Medicine, with a focus on Immunology. Later, in 2010, they studied at Imperial College London, earning a Certificate of Advanced Study in Learning and Teaching.